Maximus Earnings Up In Q1; Raises FY26 Outlook

Maximus reported Q1 FY2026 net income of $93.94M versus $41.1M a year earlier and GAAP EPS of $1.70 (adjusted EPS $1.85 vs $1.61 prior), modestly topping the $1.82 consensus, while revenue declined to $1.35B from $1.40B and missed the $1.37B estimate. Adjusted EBITDA rose to $170.41M, operating income increased to $146.21M, and management raised FY2026 adjusted diluted EPS guidance to $8.05–$8.35, narrowed revenue guidance to $5.20B–$5.35B (including a $25M divestiture impact) and improved adjusted EBITDA margin guidance by ~30 bps to ~14%, while maintaining free cash flow guidance—factors that underpin the stock's modest intraday gain.

Analysis

Market structure: Maximus (MMS) is a near-term winner — EPS guidance raised to $8.05–$8.35 implies a forward P/E ≈ 11–12x at $93.7, below many services peers, and margin guidance +30 bps to ~14% signals operational leverage that should attract multiple expansion if sustained. Losers: smaller subcontractors with less scale and legacy IT outsourcers that face fixed-cost pressure; the $25M divestiture shows MMS is pruning low-return lines and concentrating higher-margin work. Cross-asset: credit profile and free-cash-flow stability argue for tighter credit spreads (modest support to corporate IG bonds) while equity IV should compress after guidance confirmation, reducing opportunity for naked long-volatility trades.

Risk assessment: key tails are government budget shocks (sequestration-style cuts), large bid losses or protest-driven contract reversals, and integration risks from the portfolio reshuffle — each could shave 20–30% off consensus EPS if material. Time horizons: expect volatility within days of quarterly commentary and contract news, meaningful revenue visibility over the next 1–3 quarters, and structural re-rating (up or down) over 12–24 months depending on contract wins and cash conversion. Hidden dependency: revenue decline suggests timing/concentration risk in a few large contracts; watch backlog & single-client exposure metrics closely. Catalysts: quarterly updates, major contract awards/losses, and FY26 budget appropriations over next 3–9 months.

Trade implications: establish a modest overweight in MMS (2–4% portfolio) given raised EPS guide and margin expansion, but size to risk limits because revenue softness shows timing risk; target entry on pullback to $85 or place staggered buys over 2–6 weeks. Pair trade: long MMS vs short LDOS (Leidos) for 6–12 months to express stable social-services cashflows and margin leverage vs lumpy federal modernization revenue — start with equal notional positions sized to beta-neutral. Options: deploy a 6-month call spread to cap cost (buy Aug-2026 95C, sell Aug-2026 115C) sized to about 25–50% of the cash long to capture upside to $110–$120 while limiting premium risk.

Contrarian angles: consensus under-weights the quality-of-earnings story — adjusted EBITDA margin improvement plus divestiture suggests cash EPS dilution risk is limited, so market may be too pessimistic on revenue dips; conversely, upside may be one-time if margin tailwinds are cyclical. Reaction may be underdone: a 10–20% re-rating higher is plausible if next two quarters confirm revenue stabilization and continued margin expansion; but beware the risk of bid-price competition compressing margins longer-term. Unintended consequence: aggressive cost cuts to lift margins can impair future bid competitiveness, so treat any rally as conditional on sustained contract-win evidence over two subsequent quarters.

Key Decisions for Investors

• Establish a 2–4% long position in MMS (ticker MMS) over 2–6 weeks, adding on pullbacks to $85; target exit/trim at $110–$120 (≈15–25% upside) or if FY26 guidance is cut by >5% on revenue or margin.
• Initiate a pair trade: go long MMS and short LDOS (equal notional) size for 6–12 months to exploit relative stability in social-services cashflows versus lumpy federal modernization exposure; rebalance if relative performance diverges >7%.
• Buy a 6-month call spread to leverage upside with defined risk: buy Aug-2026 MMS 95C and sell Aug-2026 MMS 115C sizing premium to no more than 0.5–1% of portfolio; close if MMS < $80 or after realized IV compression >30%.
• Reduce exposure to commodity-linked or cyclical IT outsourcers (e.g., DXC-style exposures) by 1–2% and reallocate to government services names with margin-tailwinds if FY26 appropriations and contract awards in next 3–9 months remain supportive.